Clear2Cure is a biotech spin-off from Utrecht University, the Netherlands. We are developing Clearbodies®, a novel class of bispecific antibody-derived therapeutics. They are designed to capture disease targets and direct them the cell’s natural degradation system, the lysosome. Subsequently, the target is rapidly cleared for efficient and sustained therapeutic effects.
With our proprietary, modular platform, we are building a preclinical pipeline targeting diseases in the infection and immunity space that were previously considered undruggable or are poorly addressed by existing therapies. Our mission is to transform treatment options for patients facing severe infections, inflammatory disorders, and beyond.
Company Details
- Employees
- 4
- Address
- Of Utrecht University
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://clear2cure.com
Clear2cure Questions
Clear2Cure's website is http://clear2cure.com
Clear2Cure's LinkedIn profile is https://www.linkedin.com/company/clear2cure
Clear2Cure has
4 employees.
View email and phone details for 4
employees at Clear2Cure.
Clear2Cure's industry is
Biotechnology Research
Clear2Cure's top competitors are
Brodin Lab,
Utrecht Holdings,
Van Lanschot Kempen Investment Banking,
Nucleate Netherlands,
Gwen Ai,
Nucleate,
Presurgeo,
Virxcel,
Trianect,
Shape Capital Bv.
Clear2Cure's categories are Biotechnology Research
